287 related articles for article (PubMed ID: 33462760)
1. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
[TBL] [Abstract][Full Text] [Related]
2. Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model.
Baral R; Higgins D; Regan K; Pecenka C
BMJ Open; 2021 Apr; 11(4):e046563. PubMed ID: 33895717
[TBL] [Abstract][Full Text] [Related]
3. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
[TBL] [Abstract][Full Text] [Related]
4. Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.
Campbell PT; Geard N; Hogan AB
BMC Med; 2020 Nov; 18(1):319. PubMed ID: 33176774
[TBL] [Abstract][Full Text] [Related]
5. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
[TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus seasonality and its implications on prevention strategies.
Janet S; Broad J; Snape MD
Hum Vaccin Immunother; 2018 Jan; 14(1):234-244. PubMed ID: 29194014
[TBL] [Abstract][Full Text] [Related]
7. Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.
Cong B; Koç U; Bandeira T; Bassat Q; Bont L; Chakhunashvili G; Cohen C; Desnoyers C; Hammitt LL; Heikkinen T; Huang QS; Markić J; Mira-Iglesias A; Moyes J; Nokes DJ; Ploin D; ; Seo E; Singleton R; Wolter N; Fu Yung C; Zar HJ; Feikin DR; Sparrow EG; ; Nair H; Li Y;
Lancet Infect Dis; 2024 Apr; 24(4):361-374. PubMed ID: 38141633
[TBL] [Abstract][Full Text] [Related]
8. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
[TBL] [Abstract][Full Text] [Related]
9. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
[TBL] [Abstract][Full Text] [Related]
10. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus disease morbidity in Australian infants aged 0 to 6 months: a systematic review with narrative synthesis.
Self A; Van Buskirk J; Clark J; Cochrane JE; Knibbs L; Cass-Verco J; Gupta L
BMC Public Health; 2023 Dec; 23(1):2560. PubMed ID: 38129854
[TBL] [Abstract][Full Text] [Related]
12. Modelling respiratory syncytial virus age-specific risk of hospitalisation in term and preterm infants.
Giannini F; Hogan AB; Sarna M; Glass K; Moore HC
BMC Infect Dis; 2024 May; 24(1):510. PubMed ID: 38773455
[TBL] [Abstract][Full Text] [Related]
13. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA
Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043
[TBL] [Abstract][Full Text] [Related]
14. Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model.
Van Effelterre T; Hens N; White LJ; Gravenstein S; Bastian AR; Buyukkaramikli N; Cheng CY; Hartnett J; Krishnarajah G; Weber K; Pastor LH
Clin Infect Dis; 2023 Aug; 77(3):480-489. PubMed ID: 36949605
[TBL] [Abstract][Full Text] [Related]
15. Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: A sample size analysis.
Riddell CA; Bhat N; Bont LJ; Dupont WD; Feikin DR; Fell DB; Gebretsadik T; Hartert TV; Hutcheon JA; Karron RA; Nair H; Reiner RC; Shi T; Sly PD; Stein RT; Wu P; Zar HJ; Ortiz JR;
Vaccine; 2018 Dec; 36(52):8100-8109. PubMed ID: 30473186
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States.
Moghadas SM; Shoukat A; Bawden CE; Langley JM; Singer BH; Fitzpatrick MC; Galvani AP
Clin Infect Dis; 2024 May; 78(5):1328-1335. PubMed ID: 38035791
[TBL] [Abstract][Full Text] [Related]
17. The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness.
Feikin DR; Karron RA; Saha SK; Sparrow E; Srikantiah P; Weinberger DM; Zar HJ
Lancet Infect Dis; 2024 May; 24(5):e318-e327. PubMed ID: 38000374
[TBL] [Abstract][Full Text] [Related]
18. Maternal awareness, acceptability and willingness towards respiratory syncytial virus (RSV) vaccination during pregnancy in Ireland.
McCormack S; Thompson C; Nolan M; Imcha M; Dee A; Saunders J; Philip RK
Immun Inflamm Dis; 2024 Apr; 12(4):e1257. PubMed ID: 38661110
[TBL] [Abstract][Full Text] [Related]
19. A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States.
Maculaitis MC; Hauber B; Beusterien KM; Will O; Kopenhafer L; Law AW; Vietri JT; Cappelleri JC; Coulter JR; Pugh S; Shea KM
Hum Vaccin Immunother; 2024 Dec; 20(1):2358566. PubMed ID: 38847198
[TBL] [Abstract][Full Text] [Related]
20. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
Fleming JA; Baral R; Higgins D; Khan S; Kochar S; Li Y; Ortiz JR; Cherian T; Feikin D; Jit M; Karron RA; Limaye RJ; Marshall C; Munywoki PK; Nair H; Newhouse LC; Nyawanda BO; Pecenka C; Regan K; Srikantiah P; Wittenauer R; Zar HJ; Sparrow E
Vaccine; 2023 Nov; 41 Suppl 2():S7-S40. PubMed ID: 37422378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
